Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases

Frontiers in Aging Neuroscience

Volumn 5, Issue AUG, 2013, Pages

  Mariani, S ^a   Ventriglia, M ^b   Simonelli, I ^b   Spalletta, G ^c   Bucossi, S ^a   Siotto, M ^d   Assogna, F ^c   Melgari, J M ^a   Vernieri, F ^a   Squitti, R ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Alzheimer's disease; HFE; Iron; Parkinson's disease; Transferrin

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; ASPARTIC ACID; CERULOPLASMIN; CYSTEINE; HEMOCHROMATOSIS PROTEIN; HISTIDINE; IRON; IRON BINDING PROTEIN; PROLINE; SERINE; TRANSFERRIN; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HEMOCHROMATOSIS; HUMAN; IRON METABOLISM; IRON METABOLISM DISORDER; ITALY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR GENETICS; MULTICENTER STUDY; PARKINSON DISEASE; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84883493921     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2013.00037     Document Type: Article

References (66)

1. Adams, P. C., Campion, M. L., Gandon, G., LeGall, J. Y., David, V., and Jouanolle, A. M. (1997). Clinical and family studies in genetic hemochromatosis: microsatellite and HFE studies in five atypical families. Hepatology 26, 986-990. doi: 10.1002/hep.510260428
2. Ajioka, R. S., and Kushner, J. P. (2003). Clinical consequences of iron overload in hemochromatosis homozygotes. Blood 101, 3351-3353. discussion: 3354-3358. doi: 10.1182/blood-2002-11-3453
3. Albert, M., Smith, L. A., Scherr, P. A., Taylor, J. O., Evans, D. A., and Funkenstein, H. H. (1991). Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int. J. Neurosci. 57, 167-178. doi: 10.3109/00207459109150691
4. Altamura, C., Squitti, R., Pasqualetti, P., Gaudino, C., Palazzo, P., Tibuzzi, F., et al. (2009). Ceruloplasmin/Transferrin system is related to clinical status in acute stroke. Stroke 40, 1282-1288. doi: 10.1161/STROKEAHA.108.536714
5. Ayton, S., Lei, P., Duce, J. A., Wong, B. X., Sedjahtera, A., Adlard, P. A., et al. (2012). Ceruloplasmin dysfunction and therapeutic potential for parkinson disease. Ann. Neurol. doi: 10.1002/ana.23817. [Epub ahead of print].
6. Barry, E., Derhammer, T., and Elsea, S. H. (2005). Prevalence of three hereditary hemochromatosis mutant alleles in the Michigan Caucasian population. Community Genet. 8, 173-179. doi: 10.1159/000086760
7. Berg, D., Hochstrasser, H., Schweitzer, K. J., and Riess, O. (2006). Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox. Res. 9, 1-13. doi: 10.1007/BF03033302
8. Bharucha, K. J., Friedman, J. K., Vincent, A. S., and Ross, E. D. (2008). Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J. Neurol. 255, 1957-1962. doi: 10.1007/s00415-009-0063-7
9. Borie, C., Gasparini, F., Verpillat, P., Bonnet, A. M., Agid, Y., Hetet, G., et al. (2002). Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 249, 801-804. doi: 10.1007/s00415-002-0704-6
10. Buchanan, D. D., Silburn, P. A., Chalk, J. B., Le Couteur, D. G., and Mellick, G. D. (2002). The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci. Lett. 327, 91-94. doi: 10.1016/S0304-3940(02)00398-1
11. Candore, G., Licastro, F., Chiappelli, M., Franceschi, C., Lio, D., Rita Balistreri, C., et al. (2003). Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech. Ageing Dev. 124, 525-528. doi: 10.1016/S0047-6374(03)00031-9
12. Castellani, R. J., Moreira, P. I., Liu, G., Dobson, J., Perry, G., Smith, M. A., et al. (2007). Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem. Res. 32, 1640-1645. doi: 10.1007/s11064-007-9360-7
13. Combarros, O., Garcia-Roman, M., Fontalba, A., Fernandez-Luna, J. L., Llorca, J., Infante, J., et al. (2003). Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 15, 151-154. doi: 10.1159/000068480
14. Dekker, M. C., Giesbergen, P. C., Njajou, O. T., van Swieten, J. C., Hofman, A., Breteler, M. M., et al. (2003). Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci. Lett. 348, 117-119. doi: 10.1016/S0304-3940(03)00713-4
15. Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., et al. (1987). Increased nigral iron content in postmortem parkinsonian brain. Lancet 2, 1219-1220.
16. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746.
17. Duce, J. A., Tsatsanis, A., Cater, M. A., James, S. A., Robb, E., Wikhe, K., et al. (2010). Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142, 857-867.
18. Fargion, S., Mandelli, C., Piperno, A., Cesana, B., Fracanzani, A. L., Fraquelli, M., et al. (1992). Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 15, 655-659.
19. Feder, J. N., Penny, D. M., Irrinki, A., Lee, V. K., Lebron, J. A., Watson, N., et al. (1998). The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. U.S.A. 95, 1472-1477.
20. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198.
21. Gibb, W. R. (1988). Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad. Med. J. 64, 345-351.
22. Graham, J. M., Paley, M. N., Grunewald, R. A., Hoggard, N., and Griffiths, P. D. (2000). Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123(Pt 12), 2423-2431.
23. Guerreiro, R. J., Bras, J. M., Santana, I., Januario, C., Santiago, B., Morgadinho, A. S., et al. (2006). Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 6:24. doi: 10.1186/1471-2377-6-24
24. Halliwell, B. (1992). Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
25. Higgins, T. (1981). Novel chromogen for serum iron determinations. Clin. Chem. 27, 1619-1620.
26. Hixson, J. E., and Vernier, D. T. (1990). Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31, 545-548.
27. Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., et al. (2004). Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63, 1912-1917.
28. Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Kruger, R., et al. (2005). Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J. 19, 1851-1853.
29. Hubel, C. A., Kozlov, A. V., Kagan, V. E., Evans, R. W., Davidge, S. T., McLaughlin, M. K., et al. (1996). Decreased transferrin and increased transferrin saturation in sera of women with preeclampsia: implications for oxidative stress. Am. J. Obstet. Gynecol. 175(3 Pt 1): 692-700.
30. Jin, L., Wang, J., Jin, H., Fei, G., Zhang, Y., Chen, W., et al. (2012). Nigral iron deposition occurs across motor phenotypes of Parkinson's disease. Eur. J. Neurol. 19, 969-976.
31. Jin, L., Wang, J., Zhao, L., Jin, H., Fei, G., Zhang, Y., et al. (2011). Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 134(Pt 1), 50-58.
32. Johnstone, D., and Milward, E. A. (2010). Molecular genetic approaches to understanding the roles and regulation of iron in brain health and disease. J. Neurochem. 113, 1387-1402.
33. Kaur, D., and Andersen, J. (2004). Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev. 3, 327-343.
34. Kauwe, J. S., Bertelsen, S., Mayo, K., Cruchaga, C., Abraham, R., Hollingworth, P., et al. (2010). Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 955-959.
35. Kozlov, A. V., Sergienko, V. I., Vladimirov, I. U. A., and Azizova, O. A. (1984). [The antioxidant system of transferrin-ceruloplasmin in experimental hypercholesterolemia]. Biull. Eksp. Biol. Med. 98, 668-671.
36. Lavados, M., Guillon, M., Mujica, M. C., Rojo, L. E., Fuentes, P., and Maccioni, R. B. (2008). Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J. Alzheimers Dis. 13, 225-232.
37. Lehmann, D. J., Schuur, M., Warden, D. R., Hammond, N., Belbin, O., Kolsch, H., et al. (2012). Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiol. Aging 33, 202.e201-213.
38. Levenson, C. W., and Tassabehji, N. M. (2004). Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res. Rev. 3, 251-263.
39. Loeffler, D. A., DeMaggio, A. J., Juneau, P. L., Brickman, C. M., Mashour, G. A., Finkelman, J. H., et al. (1994). Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis. Assoc. Disord. 8, 190-197.
40. Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Sima, A. A., Nguyen, H. U., DeMaggio, A. J., et al. (1996). Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 738, 265-274.
41. Mariani, S., Ventriglia, M., Simonelli, I., Donno, S., Bucossi, S., Vernieri, F., et al. (2013). Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiol. Aging 34, 632-633.
42. Marklova, E., Albahri, Z., and Valis, M. (2012). Microheterogeneity of some serum glycoproteins in neurodegenerative diseases. J. Neurol. Sci. 314, 20-25.
43. Martinez-Hernandez, R., Montes, S., Higuera-Calleja, J., Yescas, P., Boll, M. C., Diaz-Ruiz, A., et al. (2011). Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study. Neurochem. Res. 36, 2111-2115.
44. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
45. Mueller, C., Schrag, M., Crofton, A., Stolte, J., Muckenthaler, M. U., Magaki, S., et al. (2012). Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J. Alzheimers Dis. 29, 341-350.
46. Namekata, K., Imagawa, M., Terashi, A., Ohta, S., Oyama, F., and Ihara, Y. (1997). Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum. Genet. 101, 126-129. doi: 10.1007/s004390050600
47. Niederau, C., Fischer, R., Purschel, A., Stremmel, W., Haussinger, D., and Strohmeyer, G. (1996). Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110, 1107-1119. doi: 10.1053/gast.1996.v110.pm8613000
48. Péran, P., Cherubini, A., Assogna, F., Piras, F., Quattrocchi, C., Peppe, A., et al. (2010). Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133, 3423-3433.
49. Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., et al. (2001). Current concepts in mild cognitive impairment. Arch. Neurol. 58, 1985-1992. doi: 10.1001/archneur.58.12.1985
50. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308. doi: 10.1001/archneur.56.3.303
51. Phatak, P. D., Ryan, D. H., Cappuccio, J., Oakes, D., Braggins, C., Provenzano, K., et al. (2002). Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol. Dis. 29, 41-47. doi: 10.1006/bcmd.2002.0536
52. Portet, F., Ousset, P. J., Visser, P. J., Frisoni, G. B., Nobili, F., Scheltens, P., et al. (2006). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J. Neurol. Neurosurg. Psychiatr. 77, 714-718. doi: 10.1136/jnnp.2005.085332
53. Raven, E. P., Lu, P. H., Tishler, T. A., Heydari, P., and Bartzokis, G. (2013). Increased iron levels and decreased tissue integrity in hippocampus of alzheimer's disease detected in vivo with magnetic resonance imaging. J. Alzheimers Dis. doi: 10.3233/JAD-130209. [Epub ahead of print].
54. Rhodes, S. L., and Ritz, B. (2008). Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol. Dis. 32, 183-195. doi: 10.1016/j.nbd.2008.07.001
55. Robson, K. J., Lehmann, D. J., Wimhurst, V. L., Livesey, K. J., Combrinck, M., Merryweather-Clarke, A. T., et al. (2004). Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J. Med. Genet. 41, 261-265. doi: 10.1136/jmg.2003.015552
56. Rossini, P. M., Buscema, M., Capriotti, M., Grossi, E., Rodriguez, G., Del Percio, C., et al. (2008). Is it possible to automatically distinguish resting EEG data of normal elderly vs. mild cognitive impairment subjects with high degree of accuracy? Clin. Neurophysiol. 119, 1534-1545. doi: 10.1016/j.clinph.2008.03.026
57. Salvador, G. A., Uranga, R. M., and Giusto, N. M. (2010). Iron and mechanisms of neurotoxicity. Int J Alzheimers Dis 2011:720658. doi: 10.4061/2011/720658
58. Sampietro, M., Caputo, L., Casatta, A., Meregalli, M., Pellagatti, A., Tagliabue, J., et al. (2001). The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol. Aging 22, 563-568. doi: 10.1016/S0197-4580(01)00219-6
59. Schrag, M., Mueller, C., Oyoyo, U., Smith, M. A., and Kirsch, W. M. (2011). Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog. Neurobiol. 94, 296-306. doi: 10.1016/j.pneurobio.2011.05.001
60. Simo, J. M., Joven, J., Cliville, X., and Sans, T. (1994). Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer. Clin. Chem. 40, 625-629.
61. Skikne, B. S., Flowers, C. H., and Cook, J. D. (1990). Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 75, 1870-1876.
62. Smith, M. A., Zhu, X., Tabaton, M., Liu, G., McKeel, D. W. Jr., Cohen, M. L., et al. (2010). Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19, 363-372.
63. Squitti, R. (2012). Metals in Alzheimer's disease: a systemic perspective. Front. Biosci. 17:451-472. doi: 10.2741/3938
64. Wolf, P. L. (1982). Ceruloplasmin: methods and clinical use. Crit. Rev. Clin. Lab. Sci. 17, 229-245. doi: 10.3109/10408368209107037
65. Zecca, L., Gallorini, M., Schunemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., et al. (2001). Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76, 1766-1773. doi: 10.1046/j.1471-4159.2001.00186.x
66. Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R., and Crichton, R. R. (2004). Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873. doi: 10.1038/nrn1537